Health Canada authorisation of Radicava oral suspension for the treatment of amyotrophic lateral sclerosis
Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. announced that Health Canada has granted market authorization for Radicava Oral Suspension, the oral formulation of Radicava V (edaravone), for the treatment of patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease that currently has no cure and can progress rapidly
MTP-CA is working to make Radicava Oral Suspension commercially available in Canada as soon as possible. Granted a Notice of Compliance (NOC) following Priority Review, Radicava Oral Suspension was developed to have similar efficacy to Radicava IV Infusion, which was authorized by Health Canada for the treatment of ALS in October 2018 and has shown in a pivotal trial to help slow the loss of physical function in ALS.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma